197 related articles for article (PubMed ID: 15603259)
1. Purine nucleoside phosphorylase inhibitors in T-cell malignancies.
Bantia S; Kilpatrick JM
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):243-7. PubMed ID: 15603259
[TBL] [Abstract][Full Text] [Related]
2. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies.
Bantia S; Parker C; Upshaw R; Cunningham A; Kotian P; Kilpatrick JM; Morris P; Chand P; Babu YS
Int Immunopharmacol; 2010 Jul; 10(7):784-90. PubMed ID: 20399911
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor--BCX-1777.
Bantia S; Ananth SL; Parker CD; Horn LL; Upshaw R
Int Immunopharmacol; 2003 Jun; 3(6):879-87. PubMed ID: 12781704
[TBL] [Abstract][Full Text] [Related]
4. Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor.
Galmarini CM
IDrugs; 2006 Oct; 9(10):712-22. PubMed ID: 17016779
[TBL] [Abstract][Full Text] [Related]
5. Functional and mechanistic studies on the toxicity of deoxyguanosine for the in vitro proliferation and differentiation of human peripheral blood B lymphocytes.
Scharenberg JG; Spaapen LJ; Rijkers GT; Duran M; Staal GE; Zegers BJ
Eur J Immunol; 1986 Apr; 16(4):381-7. PubMed ID: 3084280
[TBL] [Abstract][Full Text] [Related]
6. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent.
Bantia S; Miller PJ; Parker CD; Ananth SL; Horn LL; Kilpatrick JM; Morris PE; Hutchison TL; Montgomery JA; Sandhu JS
Int Immunopharmacol; 2001 Jun; 1(6):1199-210. PubMed ID: 11407314
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent.
Gandhi V; Balakrishnan K
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S8-12. PubMed ID: 18086347
[TBL] [Abstract][Full Text] [Related]
8. Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma.
Ravandi F; Gandhi V
Expert Opin Investig Drugs; 2006 Dec; 15(12):1601-13. PubMed ID: 17107284
[TBL] [Abstract][Full Text] [Related]
9. A comparison of some leucocyte differentiation markers and the adenosine deaminase and purine nucleoside phosphorylase values in B and T cell leukemias and lymphomas.
Mesárosová A; Hrivnáková A; Babusíková O
Neoplasma; 1995; 42(6):307-12. PubMed ID: 8592572
[TBL] [Abstract][Full Text] [Related]
10. Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents.
Schramm VL
Biochim Biophys Acta; 2002 Jul; 1587(2-3):107-17. PubMed ID: 12084452
[TBL] [Abstract][Full Text] [Related]
11. Effect of 9-benzyl-9-deazaguanine, a potent inhibitor of purine nucleoside phosphorylase, on the cytotoxicity and metabolism of 6-thio-2'-deoxyguanosine.
Parker WB; Allan PW; Niwas S; Montgomery JA; Bennett LL
Cancer Res; 1994 Apr; 54(7):1742-5. PubMed ID: 8137289
[TBL] [Abstract][Full Text] [Related]
12. Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application.
Korycka A; Błoński JZ; Robak T
Mini Rev Med Chem; 2007 Sep; 7(9):976-83. PubMed ID: 17897085
[TBL] [Abstract][Full Text] [Related]
13. In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP.
Bantia S; Montgomery JA; Johnson HG; Walsh GM
Immunopharmacology; 1996 Oct; 35(1):53-63. PubMed ID: 8913795
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative activity of purine nucleoside phosphorylase multisubstrate analogue inhibitors containing difluoromethylene phosphonic acid against leukaemia and lymphoma cells.
Glavas-Obrovac L; Suver M; Hikishima S; Hashimoto M; Yokomatsu T; Magnowska L; Bzowska A
Chem Biol Drug Des; 2010 Apr; 75(4):392-9. PubMed ID: 20102369
[TBL] [Abstract][Full Text] [Related]
15. The effect of deoxyguanosine on human lymphocyte function. II. Analysis of the interference with B lymphocyte differentiation in vitro.
Spaapen LJ; Rijkers GT; Staal GE; Rijksen G; Duran M; Stoop JW; Zegers BJ
J Immunol; 1984 May; 132(5):2318-23. PubMed ID: 6425400
[TBL] [Abstract][Full Text] [Related]
16. Effects of purine nucleoside phosphorylase deficiency on thymocyte development.
Papinazath T; Min W; Sujiththa S; Cohen A; Ackerley C; Roifman CM; Grunebaum E
J Allergy Clin Immunol; 2011 Oct; 128(4):854-863.e1. PubMed ID: 21868080
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of 2'-deoxyguanosine cytotoxicity by a novel inhibitor of purine nucleoside phosphorylase, 8-amino-9-benzylguanine.
Shewach DS; Chern JW; Pillote KE; Townsend LB; Daddona PE
Cancer Res; 1986 Feb; 46(2):519-23. PubMed ID: 3079664
[TBL] [Abstract][Full Text] [Related]
18. Correction of proliferative responses in purine nucleoside phosphorylase (PNP)-deficient T lymphocytes by retroviral-mediated PNP gene transfer and expression.
Nelson DM; Butters KA; Markert ML; Reinsmoen NL; McIvor RS
J Immunol; 1995 Mar; 154(6):3006-14. PubMed ID: 7876563
[TBL] [Abstract][Full Text] [Related]
19. Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies.
Furman RR; Hoelzer D
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S29-34. PubMed ID: 18086344
[TBL] [Abstract][Full Text] [Related]
20. Comparison of in vivo efficacy of BCX-1777 and cyclosporin in xenogeneic graft-vs.-host disease: the role of dGTP in antiproliferative action of BCX-1777.
Banti S; Miller PJ; Parker CD; Ananth SL; Horn LL; Babu YS; Sandhu JS
Int Immunopharmacol; 2002 Jun; 2(7):913-23. PubMed ID: 12188033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
